OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	1692
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	1481
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	1346
Retracted	847
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	537
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	450
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	374
Efficacy and safety of infliximab in patients with autoimmune hepatitis	293
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	227
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	215
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	205
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	205
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	196
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	188
Cover Image	174
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	170
Late-Breaking Abstracts	169
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	168
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	167
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	162
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	160
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	157
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	157
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	154
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	140

REPLY:	135
Reply	131
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	131
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	130
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	129
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	124
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	124
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	122
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	122
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	121
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	121
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	120
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	118
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	118
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	117
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	113
Access to technology to support telehealth in areas without specialty care for liver disease	111
Regulatory role and translational potential of CCL11 in liver fibrosis	108
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	107
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	105
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	105
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	105
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	103
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	103
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	102
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	98
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	98
	98
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	97
	96
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	96
Letter to the editor	94
Instructions to Authors	94
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	93
Erratum	92
Healthy peribiliary glands are necessary for successful liver transplantation	92
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	86
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	86
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	86
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	84
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	83
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	83
Letter to the Editor: Overlooking the important factor: Hypoxia	82
Reply	82
REPLY:	81
In vivo imaging of calcium dynamics in zebrafish hepatocytes	80
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	80
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	79
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	79
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	78

Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	78
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	77
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	77